A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service
Biological therapies have significantly improved the quality of life of patients with aggressive collagen vascular diseases. Blocking TNF activity may potentially confer a higher malignant potential for patients.
To identify patients to whom anti-TNF therapies were recently prescribed and were referred to a multidisciplinary lung cancer service.
Retrospective review of patients over an 18-month period who were referred to a multidisciplinary lung cancer service.
Three patients who underwent recent anti-TNF therapies and presented with solid organ tumours. All had significant additional risks for cancer including smoking and family history and active connective tissue diseases with a past history of immunosuppressive therapies.
Our series highlights the potential malignant risk of anti-TNF theraphy to a general medical audience
KeywordsAnti-TNF therapy Rheumatoid arthritis Solid organ tumours Clinical registers
SCD is supported by the Health Research Board (HRB) of Ireland and Science Foundation Ireland (SFI).
Conflict of interest
None of the authors or any commercial party have any benefit to disclosing this information.
- 2.O’Malley WE, Achinstein B, Shear MJ (1962) Action of bacterial polysaccharide on tumors, II. Damage of Sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst 29:1169–1175Google Scholar
- 5.FDA Advisory Board (2009) Follow-up to the June 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174449
- 6.Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20:119–130PubMedCrossRefGoogle Scholar
- 7.Lunt M, Watson KD, Dixon WG, Symmons DPM, Hyrich KL (2010) No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthr Rheum 62:3145–3153CrossRefGoogle Scholar
- 8.Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A (2010) BSRBR Control Centre Consortium, Symmons DPM, the BSR Biologics Register: drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-tnf therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522–528PubMedCrossRefGoogle Scholar